Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension-Reference-Cited by-同舟云学术

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

Published:2021-10-30 Issue:1 Volume:39 Page:796-810
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Galiè Nazzareno,Gaine Sean,Channick Richard,Coghlan J. Gerry,Hoeper Marius M.,Lang Irene M.,McLaughlin Vallerie V.,Lassen Cheryl,Rubin Lewis J.,Hsu Schmitz Shu-Fang,Sitbon Olivier,Tapson Victor F.,Chin Kelly M.

Funder

actelion pharmaceuticals, ltd, a janssen pharmaceutical company of johnson & johnson

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01898-1.pdf

Reference14 articles.

1. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148:1043–54. https://doi.org/10.1378/chest.15-0300.

2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142:448–56. https://doi.org/10.1378/chest.11-1460.

3. Uptravi USPI. Uptravi® (selexipag) prescribing information. 2021.